Cargando…

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis

PURPOSE: To compare adherence and persistence among patients with multiple sclerosis (MS) initiated on disease-modifying therapy (DMTs), including intramuscular (IM) interferon beta-1a (IFNβ-1a), subcutaneous (SC) IFNβ-1a, IFNβ-1b, or glatiramer acetate (GA). METHODS: MS patients initiated on IM-IFN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halpern, Rachel, Agarwal, Sonalee, Dembek, Carole, Borton, Leigh, Lopez-Bresnahan, Maria
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058604/ https://www.ncbi.nlm.nih.gov/pubmed/21423591 http://dx.doi.org/10.2147/PPA.S15702

Ejemplares similares

Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
por: Engmann, Natalie J, et al.
Publicado: (2021)

Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
por: Zanga, Gisela, et al.
Publicado: (2021)

Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis
por: Becker III, Russell V., et al.
Publicado: (2011)

Hospitalization Risk for Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics as Adjunctive Therapy with Mood Stabilizers: A Retrospective Analysis of Medicaid Claims Data
por: Niu, Xiaoli, et al.
Publicado: (2021)

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis
por: Fox, Robert J., et al.
Publicado: (2022)

A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies
por: Duquette, Pierre, et al.
Publicado: (2019)

Sacroiliac joint fusion health care cost comparison prior to and following surgery: an administrative claims analysis
por: Buysman, Erin K, et al.
Publicado: (2018)

The Association of Adherence to Osteoporosis Therapies with Fracture, All-Cause Medical Costs, and All-Cause Hospitalizations: A Retrospective Claims Analysis of Female Health Plan Enrollees with Osteoporosis
por: Halpern, Rachel, et al.
Publicado: (2011)

Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis
por: Fox, David, et al.
Publicado: (2022)

Effect of Medication Copayment on Adherence and Discontinuation in Medicare Beneficiaries with Type 2 Diabetes: A Retrospective Administrative Claims Database Analysis
por: Pawaskar, Manjiri D., et al.
Publicado: (2018)

Using Administrative Claims to Model Health-Related Behaviors: Measures of Screening and Medication Adherence
por: Yashkin, Arseniy
Publicado: (2021)

Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data
por: Jang, Yunjeong, et al.
Publicado: (2021)

Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study
por: Araujo, Lita, et al.
Publicado: (2022)

Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis
por: Menzin, Joseph, et al.
Publicado: (2013)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD)
por: Keyloun, Katelyn R., et al.
Publicado: (2017)

Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases
por: Moran, Kellyn, et al.
Publicado: (2019)

Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs
por: Munsell, Michael, et al.
Publicado: (2017)

Multiple Medication Adherence and Related Outcomes in Community-Dwelling Older People on Chronic Polypharmacy: A Retrospective Cohort Study on Administrative Claims Data
por: Franchi, Carlotta, et al.
Publicado: (2022)

Development of a novel algorithm to determine adherence to chronic pain treatment guidelines using administrative claims
por: Margolis, Jay M, et al.
Publicado: (2017)

Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence
por: Liseno, Jacob, et al.
Publicado: (2021)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Comment on: “Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases”
por: Woolcott, John, et al.
Publicado: (2020)

Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis
por: Gor, Deval, et al.
Publicado: (2020)

Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis
por: Brooks, Benjamin Rix, et al.
Publicado: (2022)

Social determinants of patiromer adherence and abandonment: An observational, retrospective, real-world claims analysis
por: Kleinman, Nathan, et al.
Publicado: (2023)

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis
por: Sussman, D., et al.
Publicado: (2017)

PB2081: TREATMENT PERSISTENCE AND ADHERENCE TO IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA: A GERMAN CLAIMS DATA ANALYSIS
por: Buske, C., et al.
Publicado: (2022)

Medication adherence/persistence among patients with active multiple sclerosis in Finland
por: Lahdenperä, Sanni, et al.
Publicado: (2020)

Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study
por: Hansen, Kerstin, et al.
Publicado: (2015)

Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
por: Stephenson, Judith J, et al.
Publicado: (2012)

Response to “Comment on Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases”
por: Moran, Kellyn, et al.
Publicado: (2020)

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
por: Freeman, Leorah, et al.
Publicado: (2021)

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
por: Morillo Verdugo, Ramón, et al.
Publicado: (2019)

Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database
por: Fan, Tao, et al.
Publicado: (2013)

Persistence and Compliance with Pazopanib in Patients with Advanced Renal Cell Carcinoma Within a U.S. Administrative Claims Database
por: Hackshaw, Michelle D., et al.
Publicado: (2014)

Adherence to Antiretroviral Therapy in Managed Care Members in the United States: A Retrospective Claims Analysis
por: Cooke, Catherine E., et al.
Publicado: (2014)

Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis
por: Foley, John F, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_iqt1sij54jsq1jbel708sc5hgh